Featuring perspectives from Dr Mazyar Shadman, including the following topics:

• The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)
• The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)
• Zanubrutinib-based therapy for treatment-naïve CLL (12:32)

CME information and select publications

Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

• Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)
• Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22)
• Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02)

CME information and select publications

Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:

• Introduction (0:00)
• Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)
• Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)
• Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)
• Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24)

CME information and select publications

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:

• Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)
• Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)
• Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)
• Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)
• Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)
• Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)
• Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)

CME information and select publications

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:

• Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)
• Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)
• Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23)
• Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48)

CME information and select publications

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:

• Introduction (0:00)
• Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)
• Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)

CME information and select publications

Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics:

• Introduction (0:00)
• Systemic Mastocytosis — Dr Hunter (9:33)
• Myelofibrosis — Dr Yacoub (29:40)

CME information and select publications

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:

• Introduction (0:00)
• Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)
• Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)

CME information and select publications

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:

• Introduction (0:00)
• Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)
• Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)

CME information and select publications

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:

• Introduction (0:00)
• Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)
• Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)
• Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)
• CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33)
• Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44)
• Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34)

CME information and select publications